Adverse effects observed in trials include: Nausea and vomiting particularly during dose escalation Diarrhoea or constipation Decreased appetite Injection site reactions Fatigue and dizziness Gallbladder-related events (including gallstones), consistent with effects observed with other GLP-1based therapies [9] Rare cases of pancreatitis , a risk associated with the GLP-1 receptor agonist class [10] [3] Because retatrutide is not licensed in the UK, the MHRA has not issued specific prescribing or dosing guidance for this compound
This makes it a strong option for those dealing with gut inflammation, poor nutrient absorption, or digestive discomfort that has not responded to conventional approaches
TB-500, GHK-Cu, and AOD-9604 require injection
References to published research throughout this description are provided for informational and research context only and do not constitute medical claims or endorsements of any therapeutic application of this product.
Young athletes, however, fall under strict NCAA/WADA guidelines because anything that influences GH pulses is considered performance-altering